Tokyo Tape
Sign in
← Medipal Holdings

Quarterly report · Q2

7459.TEDINET S100S94Y
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥1.78T2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥3.36T2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥1.69T2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥20.6bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥25.5bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥29.3bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥65.1bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥33.3bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥32.8bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥33.3bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥17.2bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥38.8bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥17.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥22.5bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥21.9bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥1.82Tat 2023-09-30Cons.Assets
Total assets¥1.71Tat 2023-03-31Cons.Assets
Total assets¥1.74Tat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥1.10Tat 2023-09-30Cons.Liabilities
Total liabilities¥1.02Tat 2023-03-31Cons.Liabilities
Net assets / equity¥714.6bnat 2023-09-30Cons.Net assets
Net assets / equity¥688.1bnat 2023-03-31Cons.Net assets
Net assets / equity¥674.7bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥209.1bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥195.0bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥207.0bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥193.6bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥238.5bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥260.4bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥31.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥16.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥9.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥10.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥39.5bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥5.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥12.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥43.5bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥6.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥80.482023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥28.082023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥184.822022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥82.512022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥43.132022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥179.122022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥77.562022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio32.1%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio32.8%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio31.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥1.2bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥1.2bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥37m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥56.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥56.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.5bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥583.4bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥583.3bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥146m
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥1.14T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.14T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1.1bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥5.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥1.78T
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥1.78T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥1.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥20.7bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥2.0bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥2.0bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥191m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥36.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥36.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥1.4bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥554.9bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥554.7bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥174m
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥12.0bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥1.10T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.09T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1.8bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥12.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥1.69T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥1.69T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥2.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥25.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 508
ItemContextValueUnit
LiabilitiesCurrentQuarterInstant1101164000000JPY
Capital stockPrior1YearInstant22398000000JPY
Capital stockCurrentQuarterInstant22398000000JPY
Capital surplusPrior1YearInstant101597000000JPY
Capital surplusCurrentQuarterInstant102147000000JPY
Retained earningsPrior1YearInstant414723000000JPY
Retained earningsCurrentQuarterInstant426877000000JPY
Treasury stockPrior1YearInstant-26288000000JPY
Treasury stockCurrentQuarterInstant-25060000000JPY
Shareholders equityPrior1YearInstant512430000000JPY
Shareholders equityCurrentQuarterInstant526363000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant61439000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant68194000000JPY
Deferred gains or losses on hedgesPrior1YearInstant5000000JPY
Deferred gains or losses on hedgesCurrentQuarterInstant229000000JPY
Revaluation reserve for landPrior1YearInstant-13700000000JPY
Revaluation reserve for landCurrentQuarterInstant-13530000000JPY
Foreign currency translation adjustmentPrior1YearInstant1547000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant1929000000JPY
Remeasurements of defined benefit plansPrior1YearInstant-364000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant-243000000JPY
Valuation and translation adjustmentsPrior1YearInstant48927000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant56580000000JPY
Non controlling interestsPrior1YearInstant126697000000JPY
Non controlling interestsCurrentQuarterInstant131673000000JPY
Net assetsPrior1YearInstant688055000000JPY
Net assetsCurrentQuarterInstant714616000000JPY
Liabilities and net assetsPrior1YearInstant1709658000000JPY
Liabilities and net assetsCurrentQuarterInstant1815781000000JPY
Net salesPrior1YTDDuration1685396000000JPY
Net salesCurrentYTDDuration1778989000000JPY
Cost of salesPrior1YTDDuration1573846000000JPY
Cost of salesCurrentYTDDuration1657614000000JPY
Gross profitPrior1YTDDuration111550000000JPY
Gross profitCurrentYTDDuration121375000000JPY
Salaries and allowances sgaPrior1YTDDuration32051000000JPY
Salaries and allowances sgaCurrentYTDDuration35641000000JPY
Welfare expenses sgaPrior1YTDDuration6278000000JPY
Welfare expenses sgaCurrentYTDDuration7002000000JPY
Provision for bonuses sgaPrior1YTDDuration6649000000JPY
Provision for bonuses sgaCurrentYTDDuration7173000000JPY
Retirement benefit expenses sgaPrior1YTDDuration1500000000JPY
Retirement benefit expenses sgaCurrentYTDDuration1925000000JPY
Distribution expenses sgaPrior1YTDDuration9562000000JPY
Distribution expenses sgaCurrentYTDDuration9835000000JPY
Rents sgaPrior1YTDDuration2048000000JPY
Rents sgaCurrentYTDDuration2419000000JPY
Depreciation sgaPrior1YTDDuration6064000000JPY
Depreciation sgaCurrentYTDDuration6604000000JPY
Other sgaPrior1YTDDuration21851000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass